Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

In this study, researchers found that combining cryotherapy with triamcinolone injections is equally effective as triamcinolone alone for treating patchy alopecia areata on the scalp and face, with no significant difference in outcomes between the two methods.

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

This report documented a successful and sustained hair restoration surgery using follicular unit transplantation for temporal triangular alopecia, lasting over six years.

In this study, basal cell carcinoma developed in Ptch-deficient mice only after chemical treatment, not skin wounding, suggesting a second unknown event is necessary for tumor formation.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

In this study, researchers developed a collagen and bacterial cellulose-based dressing loaded with bacitracin, which exhibited enhanced antibacterial activity, improved wound healing, and reduced inflammation in a murine infected-wound model, suggesting its potential for clinical use in treating infected wounds.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study observed that combining botulinum toxin type A with Minoxidil significantly promoted hair growth, improved quality of life, and enhanced patient satisfaction in male androgenetic alopecia patients at 4 and 6 months, with no adverse effects compared to using Minoxidil alone.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that radiofrequency microneedling significantly enhanced the absorption of topical triamcinolone acetonide, with insertion depth being more influential than RF energy levels.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study found that betamethasone increased tyrosinase activity and melanin content in amelanotic melanocytes from human hair follicles, suggesting a potential mechanism for glucocorticoid treatment in vitiligo.

This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects.

In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

This study reported that black hairy tongue was rapidly resolved with topical triamcinolone acetonide, suggesting further trials for its treatment are warranted.

This study found that BCG injection in COVID-19 convalescent adults reduced long COVID symptoms like hearing and cognitive issues but also led to increased hair loss in women at six months.

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.